Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Multivariate Cox proportional hazards regression analysis of MACEs

From: Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy

ModelPCSK9 1-SD increasePCSK9 T1PCSK9 T2PCSK9 T3
Crude1.92 (1.43–2.57)1.00 (Reference)2.57 (0.90–7.33)4.44 (1.62–12.18)
Model 11.99 (1.46–2.68)1.00 (Reference)2.76 (0.96–7.95)4.85 (1.74–13.54)
Model 21.95 (1.41–2.70)1.00 (Reference)2.94 (1.00–8.63)3.93 (1.35–11.42)*
Model 31.86 (1.29–2.69)*1.00 (Reference)3.36 (1.11–10.22)*3.76 (1.16–12.27)*
Model 41.86 (1.31–2.65)*1.00 (Reference)3.30 (1.09–10.01)*3.70 (1.16–11.82)*
  1. *p < 0.05; p < 0.01
  2. Model 1 adjusted for age and sex; Model 2 adjusted for Model 1 plus body mass index, baseline statin use, prior coronary artery disease, hypertension, diabetes and current smoking; Model 3 adjusted for Model 2 plus low- and high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, lipoprotein (a) and high sensitivity C-reactive protein; Model 4 adjusted for Model 3 plus genetic mutations. PCSK9, proprotein convertase subtilisin-kexin type 9; MACE: major adverse cardiovascular events